Generation and characterization of a monoclonal antibody that recognizes an activation antigen expressed by a majority of adherent lymphokine-activated killer cells

被引:2
|
作者
Chan, CS [1 ]
Kane, KP [1 ]
机构
[1] Univ Alberta, Dept Med Microbiol & Immunol, Fac Med, Edmonton, AB T6G 2S2, Canada
来源
HYBRIDOMA | 2000年 / 19卷 / 01期
关键词
D O I
10.1089/027245700315798
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In an attempt to generate murine natural killer (NK) cell-specific monoclonal antibodies (MAbs) by immunizing Balb/c mice with C57BL/6 (B6) A-LAKs, we have isolated a hybridoma, CS/NicT.2, which secretes an IgM that recognizes a majority of B6 and B6 Rag-1(-/-) A-LAKs. The CS/NicT.2 antigen is highly expressed by A-LAKs, but only at extremely low levels on resting splenocytes, suggesting that its expression is tightly associated with IL-2 activation, Among the cell lines examined, only CTLL-2 expresses the CS/NicT.2 antigen at relatively high levels. A low level of CS/NicT.2 staining is also detected on resting allo-specific cytotoxic T lymphocytes (CTL) clones, AB.1 and C11. In addition, a similar low level of CS/NicT.2 staining is detected on the T-helper cell line HT-2, The CS/NicT.2 antigen is upregulated by ionomycin but not by phorbol 12-myristate 13-acetate (PMA). For the CTL clones examined, CS/NicT.2 staining is also dramatically increased by anti-TCRbeta or anti-CD3(epsilon) stimulation, Protease treatments of CTLL-2 show that this antigen is proteinase K sensitive, but relatively resistant to trypsin digestion. Furthermore, the CS/NicT.2 antigen exhibits a relatively fast turnover rate as assessed by proteinase K and cycloheximide treatments of CTLL-2, suggesting that the CS/NicT.2 antigen may have a short half-life on the cell surface.
引用
收藏
页码:49 / 61
页数:13
相关论文
共 50 条
  • [1] GENERATION AND CHARACTERIZATION OF PURIFIED ADHERENT LYMPHOKINE-ACTIVATED KILLER CELLS IN MICE
    GUNJI, Y
    VUJANOVIC, NL
    HISERODT, JC
    HERBERMAN, RB
    GORELIK, E
    JOURNAL OF IMMUNOLOGY, 1989, 142 (05): : 1748 - 1754
  • [2] MONOCLONAL-ANTIBODY TO A TRIGGERING STRUCTURE EXPRESSED ON RAT NATURAL-KILLER CELLS AND ADHERENT LYMPHOKINE-ACTIVATED KILLER CELLS
    CHAMBERS, WH
    VUJANOVIC, NL
    DELEO, AB
    OLSZOWY, MW
    HERBERMAN, RB
    HISERODT, JC
    JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (04): : 1373 - 1389
  • [3] CHARACTERIZATION OF LYMPHOKINE-ACTIVATED KILLER (LAK) CELLS
    NIKAEIN, A
    ODONNELL, RW
    RYAN, DH
    HEAL, J
    MCQUEEN, K
    MCCUNE, CS
    HUMAN IMMUNOLOGY, 1986, 17 (02) : 197 - 197
  • [4] Augmentation of cytotoxicity of lymphokine-activated killer cells by monoclonal antibody against gastric cancer
    毕锋
    张学庸
    牟震先
    吴觉平
    樊代明
    Journal of Medical Colleges of PLA, 1995, (03) : 202 - 205
  • [5] Characterization of transendothelial migratory lymphokine-activated killer cells
    Nakano, K
    Eura, M
    Chikamatsu, K
    Masuyama, K
    Ishikawa, T
    JAPANESE JOURNAL OF CANCER RESEARCH, 1996, 87 (04): : 395 - 400
  • [6] LYMPHOKINE-ACTIVATED KILLER CELLS IN RATS - GENERATION OF NATURAL-KILLER CELLS AND LYMPHOKINE-ACTIVATED KILLER CELLS FROM BONE-MARROW PROGENITOR CELLS
    SARNEVA, M
    VUJANOVIC, NL
    VANDENBRINK, MRM
    HERBERMAN, RB
    HISERODT, JC
    CELLULAR IMMUNOLOGY, 1989, 118 (02) : 448 - 457
  • [7] MONOCLONAL-ANTIBODY TARGETING OF LYMPHOKINE-ACTIVATED KILLER-CELLS FOR THE TREATMENT OF HUMAN MALIGNANCIES
    HONSIK, CJ
    REISFELD, RA
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1987, : 139 - 139
  • [8] GENERATION OF LYMPHOKINE-ACTIVATED KILLER-CELLS BY ADHERENT LGL PHENOTYPE CELLS AND NONADHERENT LYMPHOCYTES-T
    OUESLATI, R
    MAALEJ, M
    CHOUIKHA, M
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1992, 36 : 185 - 186
  • [9] GLUTAMINE REQUIREMENTS IN THE GENERATION OF LYMPHOKINE-ACTIVATED KILLER-CELLS
    JURETIC, A
    SPAGNOLI, GC
    HORIG, H
    BABST, R
    VONBREMEN, K
    HARDER, F
    HEBERER, M
    CLINICAL NUTRITION, 1994, 13 (01) : 42 - 49
  • [10] PHENOTYPIC CHARACTERIZATION OF MURINE LYMPHOKINE-ACTIVATED KILLER-CELLS
    OWENSCHAUB, LB
    ABRAHAM, SR
    HEMSTREET, GP
    CELLULAR IMMUNOLOGY, 1986, 103 (02) : 272 - 286